抗CD20单克隆抗体治疗活动性系统性红斑狼疮  

Application of anti-CD20 monoclonal antibody in the treatment of active systemic lupus erythematosus

作　　者：李洁[1] 曾学军[1] 

机构地区：[1]中国医学科学院中国协和医科大学北京协和医院内科,北京100730

出　　处：《基础医学与临床》2007年第2期206-209,共4页Basic and Clinical Medicine

摘　　要：本文对抗CD20单克隆抗体,美罗华(Rituximab)治疗系统性红斑狼疮(SLE)的免疫病理生理,临床疗效及不良反应进行分析总结。美罗华治疗近百例活动性SLE患者的结果显示,80%的SLE活动指数有明显下降,狼疮性肾炎得到临床缓解;90%的患者耐受性好。约10%的患者在输注美罗华期间有轻度过敏反应,个别患者发生严重的机会性感染。初步临床研究提示,美罗华治疗SLE是可行的,其疗效和安全性有待于大样本临床验证。To identify the clinical efficacy,immunological consequences and adverse effects of anti-CD20 monoclonal antibody in systemic lupus erythematosus. Nearly 100 patients have been reported and a 80% of them achieved marked reduction in global disease activity and clinical remission in lupus nephritis. Anti-CD20 monoclonal antibody is well tolerated in 90% of the patients, though10% of them had hypersensitivity reactions and 4 patients had severe opportunistic infection.

关 键 词：系统性红斑狼疮 抗CD20单克隆抗体 

分 类 号：R593.241[医药卫生—内科学]